February 25, 2021 10:49 AM EST
News Briefing

Xen­cor, UCLA to part­ner for new ther­a­peu­tic an­ti­bod­ies; Schrödinger ex­pands part­ner­ship with Google Cloud

Conner Mitchell

Max Gelman

Senior Editor

Seek­ing to build on the 20 clin­i­cal-stage drug can­di­dates al­ready in its pipeline, Cal­i­for­nia on­col­o­gy and au­toim­mune dis­ease-fo­cused biotech Xen­cor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times